367
Participants
Start Date
August 3, 2023
Primary Completion Date
January 31, 2029
Study Completion Date
January 31, 2029
Mavenclad
This is an observational study, participants who received cladribine tablets in routine clinical practice following the SmPC will be included.
UCL Saint Luc, Brussels
UZ Antwerpen, Edegem
AZ Groeninge vzw, Kortrijk
CHU Sart Tilman, Liège
FN u sv. Anny Brno, Brno
FN Hradec Králové, Hradec Králové
NeuropsychiatrieHK, Hradec Králové
Fakultni nemocnice Ostrava, Ostrava
Nemocnice Teplice, Teplice
University of Thrace, Medical School - Neurology Department, Alexandroupoli, Alexandroupoli
Aiginiteio' Hospital, Athens
Attikon, Athens
Evagelismos, Athens
"General Miliary Hospital of Athens 401", Athens
University of Ioannina - Neurology department, Ioannina
University Hospital of Larissa, Larissa
"General Hospital Agios Andreas", Pátrai
University of Patras, Pátrai
AHEPA University Hospital of Thessaloniki, Thessaloniki
General Hospital of Athens G.Gennimatas, Thessaloniki
Interbalkan Hospital of Thessaloniki, Thessaloniki
St Luke's Clinic, Thessaloniki
Zuyderland, Sittard-Geleen
Oddział Kliniczny Neurologii, Szpital Uniwersytecki w Krakowie, Krakow
Medical Academy Neurology Clinic, Poznan
Szpital Kliniczny Nr 1 Pomorskiego Uniwersytetu Medycznego w Szczecinie, Szczecin
Centro Hospitalar e Universitario de Coimbra, Coimbra
Centro Hospitalar Lisboa Norte Hospital de Santa Maria, Lisbon
Centro Hospitalar Universitário Lisboa Central - Hospital dos Capuchos, Lisbon
Centro Hospitalar de São João E. P. E., Porto
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
INDUSTRY